42 results on '"Zhang, Chang-Gong"'
Search Results
2. Treatment and Prognosis of Newly Diagnosed Advanced-Stage Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Real-World Study across Two Decades.
- Author
-
Wei, Yu-Ce, Qi, Fei, Chen, Bo, Zhang, Chang-Gong, Fang, Hui, Zhang, Di, Qi, Shu-Nan, Chai, Yue, Li, Ye-Xiong, and Dong, Mei
- Subjects
HEMATOPOIETIC stem cell transplantation ,PROPORTIONAL hazards models ,PROGNOSIS ,OVERALL survival ,PROGRESSION-free survival - Abstract
Introduction: Although there is now a consensus on asparaginase-based chemotherapy regimens in the treatment of advanced-stage extranodal natural killer/T-cell lymphomas (ENKTCLs), patient survival in the real-world setting is still not optimistic according to previous literature reports, and the optimal chemotherapeutic regimens and integration of different therapeutic methods under the concept of combined-modality treatment still need to be further explored and verified. Methods: Newly diagnosed stage Ⅲ/Ⅳ ENKTCL patients from Chinese National Cancer Center in the last two decades were retrospectively collected and analyzed. Overall survival (OS) and progression-free survival (PFS) were determined as primary endpoints. Log-rank tests and Cox proportional hazard models were performed to test for survival differences between subgroups and examine the univariable and multivariable associations. Results: The study included 83 newly diagnosed stage Ⅲ/Ⅳ ENKTCL patients and reported a median OS of 26.07 months and an estimated 5-year OS of 41.3% with a median follow-up of 82.13 months. First-line asparaginase-based regimens compared to non-asparaginase-based regimens significantly prolonged PFS (p = 0.007; HR = 0.48, p = 0.020) and showed a tendency to improve OS (p = 0.064; HR = 0.74, p = 0.359). Gemcitabine-based regimens also exhibited a trend toward improved PFS (p = 0.048; HR = 0.59, p = 0.164) and OS (p = 0.008; HR = 0.67, p = 0.282) compared to non-gemcitabine-based ones. The asparaginase and gemcitabine combinations yielded a 5-year OS of 55.0% and led to significantly superior PFS (p = 0.020; HR = 0.40, p = 0.022) and slightly better OS (p = 0.054; HR = 0.79, p = 0.495) compared to the remaining regimens. First-line combined-modality treatment integrating chemotherapy and radiotherapy improved PFS (p = 0.051) and OS (p = 0.036) compared to chemotherapy alone. Four autologous hematopoietic stem cell transplantation recipients reached a median OS of 58.34 months. Conclusion: Asparaginase and gemcitabine alone brought a favorable impact on PFS and OS; and the asparaginase and gemcitabine combination chemotherapy yielded the optimal efficacy, response duration, and survival outcomes. Combined-modality treatment including potent chemotherapy supplemented by radiotherapy and/or consolidative transplantation could improve prognosis in newly diagnosed advanced-stage ENKTCLs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Treatment and prognosis of newly diagnosed advanced-stage extranodal natural killer / T cell lymphoma: a single-center real-world study across two decades
- Author
-
Wei, Yu-Ce, primary, Qi, Fei, additional, Chen, Bo, additional, Zhang, Chang-Gong, additional, Fang, Hui, additional, Zhang, Di, additional, Qi, Shu-Nan, additional, Chai, Yue, additional, Li, Ye-Xiong, additional, and Dong, Mei, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Clinical features, prognostic stratification, and treatment of advanced-stage non-nasal type extranodal natural killer/T-cell lymphoma: a multi-institutional real-world study
- Author
-
Wei, Yu-Ce, primary, Liu, Wei-Xin, additional, Qi, Fei, additional, Zhang, Chang-Gong, additional, Zheng, Bao-Min, additional, Xie, Yan, additional, Chen, Bo, additional, Zhang, Di, additional, Liu, Wei-Ping, additional, Fang, Hui, additional, Chai, Yue, additional, Qi, Shu-Nan, additional, Li, Ye-Xiong, additional, Wang, Wei-Hu, additional, Song, Yu-Qin, additional, Zhu, Jun, additional, and Dong, Mei, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Intensive therapy can improve long‐term survival in newly diagnosed, advanced‐stage extranodal NK/T‐cell lymphoma: A multi‐institutional, real‐world study
- Author
-
Wei, Yu‐Ce, primary, Qi, Fei, additional, Zheng, Bao‐Min, additional, Zhang, Chang‐Gong, additional, Xie, Yan, additional, Chen, Bo, additional, Liu, Wei‐Xin, additional, Liu, Wei‐Ping, additional, Fang, Hui, additional, Qi, Shu‐Nan, additional, Zhang, Di, additional, Chai, Yue, additional, Li, Ye‐Xiong, additional, Wang, Wei‐Hu, additional, Song, Yu‐Qin, additional, Zhu, Jun, additional, and Dong, Mei, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis
- Author
-
Hu, Shao-xuan, He, Xiao-hui, Dong, Mei, Jia, Bo, Zhou, Sheng-yu, Yang, Jian-liang, Yang, Sheng, Zhang, Chang-gong, Liu, Peng, Qin, Yan, and Gui, Lin
- Published
- 2015
- Full Text
- View/download PDF
7. High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis
- Author
-
Gui, Lin, Shi, Yuan-kai, He, Xiao-hui, Lei, Ying-heng, Zhang, Hong-zhi, Han, Xiao-hong, Zhou, Sheng-yu, Liu, Peng, Yang, Jiang-liang, Dong, Mei, Zhang, Chang-gong, Yang, Sheng, and Qin, Yan
- Published
- 2014
- Full Text
- View/download PDF
8. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma
- Author
-
Dong, Mei, He, Xiao-hui, Liu, Peng, Qin, Yan, Yang, Jian-liang, Zhou, Sheng-yu, Yang, Sheng, Zhang, Chang-gong, Gui, Lin, Zhou, Li-qiang, and Shi, Yuan-kai
- Published
- 2013
- Full Text
- View/download PDF
9. Low‐dose pegylated recombinant human granulocyte‐colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open‐label, randomized, non‐inferiority trial.
- Author
-
Yang, Sheng, Chen, Shan‐shan, Zhang, Chang‐gong, Zhou, Ying‐lei, Xiu, Meng, and Zhang, Pin
- Subjects
- *
GRANULOCYTE-colony stimulating factor , *ADJUVANT chemotherapy , *GRANULOCYTES , *BREAST cancer , *CHINESE people , *LEUKOCYTE count - Abstract
Aims Methods Results Conclusion The recommended dosage of pegylated recombinant human granulocyte‐colony stimulating factor (PEG‐rhG‐CSF) for Western chemotherapy patients is 6 mg per cycle. However, for Eastern Asians, the optimal dose remains unknown.This open‐label, randomized, non‐inferiority trial (NCT05283616) enrolled Chinese female breast cancer patients receiving adjuvant chemotherapy. Participants were randomized to receive either 3 or 6 mg of PEG‐rhG‐CSF per cycle, stratified by body weight (BW; ≤60 kg
vs . >60 kg). The primary endpoint was timely absolute neutrophil count (ANC) recovery before the second cycle of chemotherapy.A total of 122 patients were randomized and 116 were included for efficacy analyses. The timely ANC recovery rate in the 3 mg arm was 89.8%, compared to 93.0% in the 6 mg arm (one‐sided 95% confidence interval [CI] lower limit for difference: −11.7%), meeting the prespecified non‐inferiority margin of 15%. The rate was 93.3% with PEG‐rhG‐CSF 3 mg and 96.6% with 6 mg in patients with BW ≤ 60 kg, and 86.2% and 89.3%, respectively, in those with BW > 60 kg. Although the incidence of severe neutropenia was similar across arms, the occurrence of excessively high ANC and white blood cell counts was higher in the 6 mg arm. No grade ≥3 adverse events related to PEG‐rhG‐CSF occurred.Three milligrams of PEG‐rhG‐CSF per cycle provided non‐inferior neutrophil protection and attenuated neutrophil overshoot compared to 6 mg doses. This low‐dose regimen could be a new supportive care option for Chinese breast cancer patients receiving anthracycline‐based adjuvant chemotherapy. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
10. Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era
- Author
-
Wang, Qin, primary, Qin, Yan, additional, Kang, Su-Yi, additional, He, Xiao-Hui, additional, Liu, Peng, additional, Yang, Sheng, additional, Zhou, Sheng-Yu, additional, Zhang, Chang-Gong, additional, Gui, Lin, additional, Yang, Jian-Liang, additional, Sun, Yan, additional, and Shi, Yuan-Kai, additional
- Published
- 2016
- Full Text
- View/download PDF
11. Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases
- Author
-
Xu, Jian‐ping, primary, Liu, Xiao‐yan, additional, Yang, Sheng, additional, Zhang, Chang‐gong, additional, Wang, Lin, additional, and Shi, Yuan‐kai, additional
- Published
- 2016
- Full Text
- View/download PDF
12. GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
- Author
-
Wang, Jing-jing, primary, Dong, Mei, additional, He, Xiao-hui, additional, Li, Ye-xiong, additional, Wang, Wei-hu, additional, Liu, Peng, additional, Yang, Jian-liang, additional, Gui, Lin, additional, Zhang, Chang-gong, additional, Yang, Sheng, additional, Zhou, Sheng-yu, additional, and Shi, Yuan-kai, additional
- Published
- 2016
- Full Text
- View/download PDF
13. Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
- Author
-
Zhou, Ping, primary, Liu, Peng, additional, Zhou, Sheng-Yu, additional, He, Xiao-Hui, additional, Han, Xiao-Hong, additional, Qin, Yan, additional, Yang, Sheng, additional, Zhang, Chang-Gong, additional, Gui, Lin, additional, Yao, Jia-Rui, additional, Zhao, Li-Ya, additional, Zhang, Shu-Xiang, additional, Sun, Yan, additional, and Shi, Yuan-Kai, additional
- Published
- 2015
- Full Text
- View/download PDF
14. Evaluation of the Boson Chemiluminescence Immunoassay as a First-Line Screening Test in the ECDC Algorithm for Syphilis Serodiagnosis in a Population with a High Prevalence of Syphilis
- Author
-
Qiu, Xin-Hui, primary, Zhang, Ya-Feng, additional, Chen, Yu-Yan, additional, Zhang, Qiao, additional, Chen, Fu-Yi, additional, Liu, Long, additional, Fan, Jin-Yi, additional, Gao, Kun, additional, Zhu, Xiao-Zhen, additional, Zheng, Wei-Hong, additional, Zhang, Hui-Lin, additional, Lin, Li-Rong, additional, Liu, Li-Li, additional, Tong, Man-Li, additional, Zhang, Chang-Gong, additional, Niu, Jian-Jun, additional, and Yang, Tian-Ci, additional
- Published
- 2015
- Full Text
- View/download PDF
15. Bcl-2/IgH Expression of Diffuse Large B-cell Lymphoma Cells in Minimal Bone Marrow Infiltration
- Author
-
Che, Yi-Qun, primary, Liu, Peng, additional, Luo, Yang, additional, Shen, Di, additional, Hao, Jia-Jie, additional, Yang, Lin, additional, Zhang, Chang-Gong, additional, Qi, Jun, additional, and Wang, Ming-Rong, additional
- Published
- 2014
- Full Text
- View/download PDF
16. High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis
- Author
-
Gui, Lin, primary, Shi, Yuan-kai, additional, He, Xiao-hui, additional, Lei, Ying-heng, additional, Zhang, Hong-zhi, additional, Han, Xiao-hong, additional, Zhou, Sheng-yu, additional, Liu, Peng, additional, Yang, Jiang-liang, additional, Dong, Mei, additional, Zhang, Chang-gong, additional, Yang, Sheng, additional, and Qin, Yan, additional
- Published
- 2013
- Full Text
- View/download PDF
17. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma
- Author
-
Dong, Mei, primary, He, Xiao-hui, additional, Liu, Peng, additional, Qin, Yan, additional, Yang, Jian-liang, additional, Zhou, Sheng-yu, additional, Yang, Sheng, additional, Zhang, Chang-gong, additional, Gui, Lin, additional, Zhou, Li-qiang, additional, and Shi, Yuan-kai, additional
- Published
- 2012
- Full Text
- View/download PDF
18. Efficacy of peripheral blood stem cell transplantation versus conventional chemotherapy on anaplastic large-cell lymphoma:a retrospective study of 64 patients from a single center
- Author
-
He, Xiao-Hui, primary, Li, Bo, additional, Zou, Shuang-Mei, additional, Dong, Mei, additional, Zhou, Sheng-Yu, additional, Yang, Jian-Liang, additional, Xue, Li-Yan, additional, Yang, Sheng, additional, Liu, Peng, additional, Qin, Yan, additional, Zhang, Chang-Gong, additional, Han, Xiao-Hong, additional, and Shi, Yuan-Kai, additional
- Published
- 2012
- Full Text
- View/download PDF
19. R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma
- Author
-
He, Xiao-Hui, primary, Li, Bo, additional, Yang, Sheng, additional, Lu, Ning, additional, Zhang, Xun, additional, Zou, Shuang-Mei, additional, Li, Ye-Xiong, additional, Song, Yong-Wen, additional, Zheng, Shan, additional, Dong, Mei, additional, Zhou, Sheng-Yu, additional, Yang, Jian-Liang, additional, Liu, Peng, additional, Zhang, Chang-Gong, additional, and Qin, Yan, additional
- Published
- 2012
- Full Text
- View/download PDF
20. Evaluation of a colloidal gold immunochromatography assay in the detection of Treponema pallidum specific IgM antibody in syphilis serofast reaction patients: a serologic marker for the relapse and infection of syphilis
- Author
-
Lin, Li-Rong, primary, Tong, Man-Li, additional, Fu, Zuo-Gen, additional, Dan, Bing, additional, Zheng, Wei-Hong, additional, Zhang, Chang-Gong, additional, Yang, Tian-Ci, additional, and Zhang, Zhong-Ying, additional
- Published
- 2011
- Full Text
- View/download PDF
21. Development of a colloidal gold-immunochromatography assay to detect immunoglobulin G antibodies to Treponema pallidum with TPN17 and TPN47
- Author
-
Lin, Li-Rong, primary, Fu, Zuo-Gen, additional, Dan, Bing, additional, Jing, Guang-Jun, additional, Tong, Man-li, additional, Chen, De-Teng, additional, Yu, Yang, additional, Zhang, Chang-Gong, additional, Yang, Tian-Ci, additional, and Zhang, Zhong-Ying, additional
- Published
- 2010
- Full Text
- View/download PDF
22. Therapeutic effects of fistular onion stalk extract on nonalcoholic fatty liver in rats
- Author
-
Shi, Zhao-Hong, primary, Wang, Xiang-Ning, additional, Zhang, Chang-Gong, additional, Lin, Li-Li, additional, Guo, Jie, additional, and Liu, Hao, additional
- Published
- 2010
- Full Text
- View/download PDF
23. Efficacy of modified Hyper-CVAD regimen on non-Hodgkin's lymphoma and safety evaluation
- Author
-
Shi, Wei, primary, Shi, Yuan-Kai, additional, He, Xiao-Hui, additional, Yang, Jian-Liang, additional, Zhang, Chang-Gong, additional, Zhou, Sheng-Yu, additional, Dong, Mei, additional, Liu, Peng, additional, Qin, Yan, additional, Yang, Sheng, additional, Gui, Lin, additional, and Lv, Zheng, additional
- Published
- 2009
- Full Text
- View/download PDF
24. [Evaluation of the role of rhIL-11 on hematological recovery in lymphoma patients after autologous hematopoietic stem cell transplantation].
- Author
-
Yang JL, Shi YK, He XH, Dong M, Zhou SY, Liu P, Zhang CG, Han XH, Yang S, Gui L, and Qin Y
- Subjects
- Adult, Female, Follow-Up Studies, Humans, Male, Platelet Count, Platelet Transfusion, Recombinant Proteins administration & dosage, Retrospective Studies, Transplantation, Autologous, Hematopoietic Stem Cell Transplantation, Interleukin-11 administration & dosage, Lymphoma therapy
- Abstract
Objective: To evaluate the effect of recombinant human interleukin 11 (rhIL-11) on hematological recovery after autologous hematopoietic stem cell transplantation (AHSCT) in patients with lymphoma., Methods: A retrospective study was carried out on 73 patients with lymphoma after AHSCT. The patients were divided into two groups. The study group (n = 35) received rhIL-11 1.5 mg daily from the fifth day after AHSCT to the day when platelets recovering to 80.0×10⁹/L. The control group (n = 38) did not receive rhIL-11 after AHSCT., Results: All the 73 patients finished AHSCT from Mar 2003 to Dec 2008 in our department. Thirty-five patients received rhIL-11 and 38 patients did not. In the rhIL-11 group and control group, the nadir of platelet was (18.9 ± 5.0)×10⁹/L and (21.5 ± 6.0)×10⁹/L, respectively, with a significant difference (P = 0.04). The median time of platelet recovering to 50.0×10⁹/L was (14.3 ± 5.5) d and (13.2 ± 4.5) d (P = 0.37) in the two groups. There was no significant difference (P = 0.82) in the median numbers of platelet transfusion in the two groups. The curves of the mean of daily absolute platelet counts of the two groups were similar (P = 0.22). Adverse events related to rhIL-11 were not found in the rhIL-11 group., Conclusion: The results of this study do not show obviously accelerating effect of rhIL-11 on the platelet recovery in lymphoma patients after AHSCT and obvious increase of adverse events after rhIL-11 administration.
- Published
- 2012
- Full Text
- View/download PDF
25. [Comparative analysis of liver function in HBsAg-/HBcAb+ patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP regimens].
- Author
-
Huang YH, He XH, Qin Y, Yang S, Lü Z, Dong M, Zhou SY, Liu P, Zhang CG, Yang JL, and Shi YK
- Subjects
- Alanine Transaminase blood, Antibodies, Monoclonal, Murine-Derived therapeutic use, Aspartate Aminotransferases blood, Bilirubin blood, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Female, Follow-Up Studies, Hepatitis B Antibodies metabolism, Hepatitis B Core Antigens immunology, Hepatitis B Surface Antigens metabolism, Humans, Liver Function Tests, Lymphoma, Large B-Cell, Diffuse blood, Lymphoma, Large B-Cell, Diffuse immunology, Lymphoma, Large B-Cell, Diffuse virology, Male, Prednisolone therapeutic use, Prednisone therapeutic use, Retrospective Studies, Rituximab, Vincristine therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Large B-Cell, Diffuse drug therapy
- Abstract
Objective: To analyze the liver function in patients with diffuse large B-cell lymphoma(DLBCL), who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive (HBsAg-/HBcAb+), treated with CHOP and R-CHOP regimens., Methods: In this retrospective study, 86 DLBCL patients, who were HBsAg-/HBcAb+, were collected from Cancer Hospital of Chinese Academy of Medical Sciences between January 2005 and December 2008. The patients were given at least two cycles of chemotherapy using CHOP-like or R-CHOP-like regimen without anti-HBV treatment, and followed-up for at least 12 months after completion of therapy., Results: Forty-seven patients received CHOP-like regimen while 39 patients received R-CHOP-like regimen. There were no significant differences in the degree of liver dysfunction between CHOP group and R-CHOP group after the 1st, 2nd, 3rd, 4th and 6th cycles (22.7% - 46.7% with CHOP and 17.6% - 34.2% with R-CHOP, respectively, (all P > 0.05), except for the 5th cycles (28.6% vs. 6.2%, P = 0.026). Liver function in most patients in CHOP group and R-CHOP group was normal after every cycle (53.3% - 77.3% and 65.8%-93.8%, respectively). Meanwhile, there were no significant differences in the degree of liver dysfunction between CHOP group and R-CHOP group in the 1st-3rd month, 4th-6th month, 7th-9th month and 10th-12th month after completion of therapy (7.7% - 40.0% with CHOP and 7.4% - 32.0% with R-CHOP, respectively, all P > 0.05)., Conclusions: The present study reveals a low incidence of liver dysfunction in HBsAg-/HBcAb+ DLBCL patients, both in CHOP group and in R-CHOP group. It may indicate a potential low incidence of HBV reactivation in these groups, and Rituximab do not increase the rate of liver dysfunction. Therefore, these data may not support regularly prophylactic antiviral therapy during chemotherapy, but close monitoring of liver function, HBV serum markers and HBV DNA level are demanded.
- Published
- 2012
- Full Text
- View/download PDF
26. Bcl-2/IgH expression in minimal bone marrow infiltration by follicular lymphoma cells.
- Author
-
Che YQ, Liu P, Wang Y, Zhang CG, Han YL, Shen D, Zhang Y, Zheng CL, Qi J, and Wang QT
- Subjects
- Adolescent, Adult, Aged, Bone Marrow Cells cytology, Bone Marrow Cells metabolism, Child, Child, Preschool, Chromosomes, Human, Pair 14, Chromosomes, Human, Pair 18, Cohort Studies, Female, Humans, Immunoglobulin Heavy Chains genetics, Immunohistochemistry, In Situ Hybridization, Fluorescence, Male, Middle Aged, Neoplasm Staging, Proto-Oncogene Proteins c-bcl-2 genetics, Translocation, Genetic, Bone Marrow Cells pathology, Gene Expression Regulation, Neoplastic, Immunoglobulin Heavy Chains metabolism, Lymphoma, Follicular physiopathology, Proto-Oncogene Proteins c-bcl-2 metabolism
- Abstract
The purpose of this study was to investigate the roles of bcl-2 chromosomal translocation and Bcl-2 protein expression in follicular lymphoma (FL) minimal bone marrow (BM) infiltration. We identified the same bcl-2/IgH fusion gene in paraffin-embedded lymph node (LN) samples and BM samples using immunohistochemistry (IHC), immunocytochemistry (ICC), cytologic morphology and fluorescence in situ hybridization (FISH). The presence of the Bcl-2/IgH fusion gene in the BM samples and paraffin-embedded LN samples from 56 patients with follicular lymphomas was detected using FISH. The Bcl-2 protein levels in BM and paraffin-embedded tissues were quantified using ICC and IHC, respectively. Approximately 78.6% (44/56) of the paraffin‑embedded LN tissue sections that underwent FISH analysis had a bcl-2/IgH translocation. The primary lesion was also positive for the bcl-2/IgH fusion gene, as were the BM minimal infiltrates. The bcl-2/IgH rearrangement occurred in 88.6% (39/44) of the BM specimens. The bcl-2/IgH recombination rate in stage III/IV cancers was significantly different to that observed in stage I/II cancers (p=0.041). In 59% (23/39) of the cases with t(14;18), Bcl-2 was found to be present as assessed by ICC. Positive Bcl-2 ICC staining and the t(14;18) translocation (as detected using FISH) were positively correlated (p=0.028). We then applied the FISH method to slides that had previously been morphologically evaluated using Wright-Giemsa staining; any slides with at least one abnormal cell were subjected to FISH analysis following staining. The assessment of bcl-2/IgH translocation status may contribute to the better detection of minimal BM infiltration by FL cells. Utilizing FISH and cytologic morphology techniques allows for earlier and more accessible BM examination.
- Published
- 2012
- Full Text
- View/download PDF
27. [Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma].
- Author
-
Qin Y, Shi YK, He XH, Yang JL, Zhang CG, Zhou SY, Liu XF, Liu P, Yang S, Zhou LQ, Han XH, and Yao JR
- Subjects
- Adult, Cyclophosphamide therapeutic use, Disease-Free Survival, Doxorubicin therapeutic use, Female, Follow-Up Studies, Humans, Immunoblastic Lymphadenopathy blood, Immunoblastic Lymphadenopathy radiotherapy, L-Lactate Dehydrogenase blood, Lymphoma, T-Cell, Peripheral blood, Lymphoma, T-Cell, Peripheral radiotherapy, Male, Middle Aged, Pneumonia etiology, Prednisone therapeutic use, Retrospective Studies, Stem Cell Transplantation, Survival Rate, Thalidomide therapeutic use, Vincristine therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Immunoblastic Lymphadenopathy drug therapy, Immunoblastic Lymphadenopathy pathology, Lymphoma, T-Cell, Peripheral drug therapy, Lymphoma, T-Cell, Peripheral pathology
- Abstract
Objective: To retrospectively analyze the clinical features and prognostic factors of patients with angioimmunoblastic T-cell lymphoma (AITL)., Methods: The clinicopathological and follow-up data of 18 AITL patients undergoing integrated treatment from Feb. 1998 to April 2009 in our department were retrospectively analyzed. All of the patients received CHOP-like regimens as initial chemotherapy, including 4 once treated with radiotherapy and 1 with high dose therapy followed by autologous stem cell transplantation (HDT-ASCT) as upfront consolidation therapy. B-cell, T-cell and NK-cell subgroup proportions in the peripheral blood were tested by flow cytometry in 6 patients., Results: The median age of the 18 patients was 55 years, male and female ratio was 2.6:1. Seventy-two percent of the patients were in an advanced stage. 72% of them had B symptoms, 69% hypergammaglobulinemia, 60% elevated LDH and 47% anemia. Forty-four percent achieved CR after initial treatment with CHOP-like regimens. With the median follow-up of 26 months, the overall 2-year survival and disease free survival (DFS) rates were 62.2% and 44.4%, respectively. In the univariate analysis, only age > 30 years and primary refractory disease adversely affected overall survival (OS); age > 30 years, advanced stage, B symptoms and splenomegaly adversely affected DFS. Four patients suffered from severe pneumonia during treatment, 2 of them died of respiratory failure. Flow cytometry of peripheral blood lymphocytes showed that 5 of the 6 tested cases had decreasing proportion of CD3(+)CD4(+) T cells, B cells and NK cells but elevated CD3(+)CD8(+) T cells. Two heavily treated patients achieved partial and complete response by thalidomide therapy, with a progression free survival (PFS) of 2 and 6+ months, respectively., Conclusion: AITL patients do not response well to CHOP-like regimens chemotherapy. Age < 30 years and sensitive to initial chemotherapy are associated with prolonged OS. Effectiveness of thalidomide in the treatment of AITL deserves further investigation. Peripheral blood lymphocytes test indicates that AITL patients suffered from both natural and acquired immune defects.
- Published
- 2010
28. [Primary cutaneous anaplastic large cell lymphoma: clinical presentation, therapy and prognosis study of 10 cases].
- Author
-
Lü Z, Shi YK, He XH, Qin Y, Zhou SY, Zhang CG, Liu P, and Yang JL
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Prognosis, Treatment Outcome, Young Adult, Lymphoma, Primary Cutaneous Anaplastic Large Cell diagnosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell therapy, Skin Neoplasms diagnosis, Skin Neoplasms therapy
- Abstract
Objective: To explore the clinical presentation, therapy and prognosis study of primary cutaneous anaplastic large cell lymphoma (PCALCL)., Methods: We reviewed and analyzed ten cases of PCALCL receiving treatment at our hospital from January 1999 to January 2009., Results: There were 8 males and 2 females with a median age of 48 years old (range: 22 - 69). There were single subcutaneous nodule (n = 7) and multiple nodules (n = 3). And the lesions could be found on head and neck (n = 5), trunk (n = 3) and all over body (n = 2). The lesions appeared red, solid and stable subcutaneous nodules. Partial lesions had a spontaneous regression and new nodules appeared at the same or different sites. Two patients had lymphadenopathy and one had bone involvement with anaplastic lymphoma kinase (ALK) positive and high cell proliferation ratio index (ki-67 > 80%). Seven cases with single lesion received surgical excision plus radiotherapy, chemotherapy or radiochemotherapy, one case recurred, six cases survived without disease. Three cases with multiple lesions received systemic chemotherapy mainly in combination with radiotherapy or biotherapy, two cases recurred and one case survived without disease. The median follow-up was 44 months (range: 9 - 95), progression free survival 89% and overall survival 100%., Conclusion: PCALCL is found more commonly in males. Visceral and lymph node involvement are rare. The patients with single lesion have a longer disease-free survival than those with multiple lesions after surgical excision in combination with chemotherapy or radiotherapy. Multiple lesions can not be cured.
- Published
- 2010
29. [Primary subcutaneous panniculitis-like T-cell cutaneous lymphoma: clinical presentation, treatment and prognosis].
- Author
-
Lü Z, Shi YK, Zhou LQ, Qin Y, Dong M, Yang JL, Liu P, and Zhang CG
- Subjects
- Adolescent, Adult, CD56 Antigen metabolism, Child, Combined Modality Therapy, Cyclophosphamide therapeutic use, Disease-Free Survival, Doxorubicin therapeutic use, Female, Follow-Up Studies, Humans, Lymphatic Diseases etiology, Lymphohistiocytosis, Hemophagocytic etiology, Lymphoma, T-Cell complications, Lymphoma, T-Cell drug therapy, Lymphoma, T-Cell metabolism, Lymphoma, T-Cell radiotherapy, Lymphoma, T-Cell surgery, Male, Middle Aged, Panniculitis complications, Panniculitis drug therapy, Panniculitis metabolism, Panniculitis radiotherapy, Panniculitis surgery, Prednisone therapeutic use, Retrospective Studies, Survival Rate, Vincristine therapeutic use, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use
- Abstract
Objective: To explore the clinical presentation, treatment and prognosis study of primary subcutaneous panniculitis-like T-cell cutaneous lymphoma (SCPTCL)., Methods: Ten cases of SCPTCL, treated in our hospital from January 1999 to January 2009, were included in this study. Their clinicopathological data were reviewed and analyzed retrospectively., Results: the median age was 50.5 years (range: 10 - 58), 4 males and 6 females. There were seven CD56 positive, two negative cases and 1 unclear case. Four cases had repeatedly nodules regressed spontaneously without treatment before diagnosis and new nodules appeared at different sites. Seven patients presented with multiple subcutaneous nodules or deeply seated plaques, most commonly on the extremities and trunk. Ulceration of nodules occurred in 3 cases, and the lesions were painful in five cases. The lesions appeared nodules at the beginning, and then gradually grew into tumors. Four patients had abnormal liver function and one patient had hemophagocytic syndrome (HPS), four patients had lymphadenopathy or visceral involvement. Three cases with single lesion underwent surgical excision in combination with chemotherapy or chemotherapy/radiotherapy. One case lost follow up, and two cases live without disease. Among the seven patients with multiple lesions, lymphadenopathy or visceral involvement, one underwent local surgical excision and is alive without disease, six of them received chemotherapy or multi-modality treatment mainly with chemotherapy. Three of these 6 cases are alive without progression, one used histone deacetylase inhibitors after progression and obtained partial regression, and 2 died. The median follow-up for all the 10 patients was 44 months (range: 14 - 99). The progression free survival was 66.7% (6/9), and overall survival was 77.8% (7/9)., Conclusion: SPTCL has an indolent course, some lesions can regress spontaneously and relapse again. Patients with single lesion may live long-term without disease after multimodality therapy. Patients with multiple lesions or extracutaneous involvement are sensitive to CHOP-like regimen, but the duration of remission is short. Histone deacetylase inhibitors may be a promising drug in the treatment for SCPTCL relapse.
- Published
- 2010
30. [A clinical report on modified Hyper-CVAD regimen in patients with lymphoblastic lymphoma].
- Author
-
Shi W, Shi YK, He XH, Zhou SY, Dong M, Zhang CG, Yang JL, Liu P, Qin Y, Yang S, and Gui L
- Subjects
- Adolescent, Adult, Cyclophosphamide adverse effects, Cyclophosphamide therapeutic use, Dexamethasone adverse effects, Dexamethasone therapeutic use, Doxorubicin adverse effects, Doxorubicin therapeutic use, Female, Humans, Male, Reproducibility of Results, Retrospective Studies, Vincristine adverse effects, Vincristine therapeutic use, Young Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
- Abstract
Objective: The efficacy of standard chemotherapy regimen on lymphoblastic lymphoma (LBL) is unsatisfied. This study was to evaluate the efficacy and safety of modified Hyper-CVAD regimen on Chinese patients with LBL., Methods: Clinical records of 20 LBL patients who received modified Hyper-CVAD regimen in Cancer Hospital of Chinese Academy of Medical Sciences, from June 2004 to June 2008, were retrospectively analyzed in terms of response and toxicity., Results: By May. 2009, the median follow-up time was 17 (4-36) months. The 20 patients totally received 62 cycles regimen A and 29 cycles regimen B. 17 patients were assessable in efficacy, the total response rate (RR) was 88.2% with complete response (CR) rate of 41.2%. 15 patients received modified Hyper-CVAD regimen as first-line therapy (75.0%), and RR was 100% with CR rate of 50.0% (7/14). The RR of salvage therapy was 33% without CR achieved. The major toxicity was myelosuppression, the incidence of grades 3-4 neutropenia, thrombocytopenia and anemia was 95.0%, 75.0% and 40.0%, respectively. No treatment-related death was observed., Conclusions: Modified Hyper-CVAD regimen was a promising regimen for the patients with LBL, and toxicity was within acceptable limits.
- Published
- 2010
31. [Efficacy of modified Hyper-CVAD regimen on non-Hodgkin's lymphoma and safety evaluation].
- Author
-
Shi W, Shi YK, He XH, Yang JL, Zhang CG, Zhou SY, Dong M, Liu P, Qin Y, Yang S, Gui L, and Lv Z
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Burkitt Lymphoma drug therapy, Burkitt Lymphoma pathology, Cyclophosphamide adverse effects, Cyclophosphamide therapeutic use, Dexamethasone adverse effects, Dexamethasone therapeutic use, Disease-Free Survival, Doxorubicin adverse effects, Doxorubicin therapeutic use, Female, Follow-Up Studies, Humans, Lymphoma, Mantle-Cell drug therapy, Lymphoma, Mantle-Cell pathology, Lymphoma, Non-Hodgkin pathology, Male, Middle Aged, Neutropenia chemically induced, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma pathology, Remission Induction, Thrombocytopenia chemically induced, Vincristine adverse effects, Vincristine therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Non-Hodgkin drug therapy, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma drug therapy
- Abstract
Background and Objective: The efficacy of standard chemotherapy regimen on aggressive non-Hodgkin's lymphoma (NHL) of certain pathologic types is unsatisfied. This study was to evaluate the safety and efficacy of modified Hyper-CVAD regimen on Chinese patients with aggressive NHL., Methods: Clinical records of 31 NHL patients who received modified Hyper-CVAD regimen in Cancer Hospital of Chinese Academy of Medical Sciences from June 2004 to June 2008 were analyzed in terms of toxicity and response., Results: The 31 patients totally received 91 cycles of regimen A and 41 cycles of regimen B with a median of 4 cycles (ranged 1-7 cycles). The major toxicity was myelosuppresion: the occurrence rates of neutropenia of grades III-IV, thrombocytopenia and febrile neutropenia were 49.5%, 3.3% and 12.1% during treatment of regimen A, and were 80.5%, 82.9% and 46.3% during treatment of regimen B. No treatment-related death was observed. The responses were assessable in 26 patients. The total response rate was 80.8%, and 12 patients achieved complete response (46.2%)., Conclusion: Modified Hyper-CVAD regimen is a promising regimen for the patients with intermediate and high grade NHL.
- Published
- 2009
- Full Text
- View/download PDF
32. [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
- Author
-
Qin Y, Shi YK, He XH, Han XH, Zhou SY, Liu P, Yang JL, Yang S, Zhang CG, Dong M, Zhou LQ, Wang JW, Feng FY, and Sun Y
- Subjects
- Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Child, Child, Preschool, Combined Modality Therapy, Cyclophosphamide administration & dosage, Cyclophosphamide therapeutic use, Disease-Free Survival, Dose-Response Relationship, Drug, Doxorubicin administration & dosage, Doxorubicin therapeutic use, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prednisone administration & dosage, Prednisone therapeutic use, Remission Induction, Retrospective Studies, Survival Rate, Vincristine administration & dosage, Vincristine therapeutic use, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Marrow pathology, Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
- Abstract
Objective: To retrospectively analyze and compare the treatment efficiency of CHOP-based regimens with or without high-dose consolidation treatment combined with hematopoietic stem cell transplantation (HDT-HSCT) in the patients with lymphoblastic lymphoma (LBL)., Methods: From 1989 to 2004, totally 63 patients with LBL were initially treated with a standard CHOP-based regimen. Forty-two of the 63 patients achieved complete response (CR), 26 of those subsequently received consolidation HDT-HSCT, while the other 16 had 6-8 cycles of standard CHOP-based treatment only., Results: Of the 63 patients, 57 had a T-LBL and 6 B-LBL, with a median age of 20 years, 19 (30.2%) had a stage I-II diseases and 44 (69.8%) stage III-IV diseases, 61.9% presented with a mediastinal mass. Bone marrow involvement presented in 28.6% of the patients. Fourteen percent had central nervous system involvement. The median follow-up period was 24 months, and the estimated 5-year overall survival and disease-free survival of this series was 31.2% and 29.3%, respectively. Of the 42 patients who achieved CR, the 5-year OS rate of the patients who received HDT-HSCT as a consolidation therapy was 59.8% versus 14.6% of the patients treated by CHOP-based regimens alone (P=0.004). Bone marrow involvement, age > or =20 years, short response duration and primary refractory disease were factors significantly associated with poor outcome. Among the 18 patients with bone marrow involvement, 3 received allogeneic HSCT and were all still alive at the follow up time of 22, 32 and 37 months, respectively, while another 4 received auto-HSCT and all died of the disease within 14 months., Conclusion: Short term treatment with a CHOP-based regimen is not sufficient for the patients with lymphoblastic lymphoma. High-dose consolidation treatment and hematopoietic stem cell transplantation may improve overall survival and disease free survival. Bone marrow involvement, age >20 years, and short response duration and primary refractory disease are all the factors significantly associated with poor outcome. For the patients with bone marrow involvement, allohematopoietic stem cell transplantation is superior to auto-hematopoietic stem cell transplantation.
- Published
- 2009
33. [Gene construction, expression and activities analysis of human leptin].
- Author
-
Wu N, Zhang CG, Xie LY, Wang Z, and Yan JH
- Subjects
- Apoptosis drug effects, Escherichia coli genetics, Humans, Leptin pharmacology, Recombinant Proteins biosynthesis, Recombinant Proteins isolation & purification, Recombinant Proteins pharmacology, Leptin genetics
- Abstract
Six 89bp primers were designed on the base of the cDNA sequence encoding the human leptin reported on the NCBI. The synthetic gene with 464bp encoding rhLep was obtained by SOE ( splicing by overlap extension) PCR. The expression vector pET22b(+)/rhLep was constructed and transformed into E. coli BL21 (DE3). The rhLep protein was expressed as inclusion bodies with the yield of more than 50% of total bacterial proteins after IPTG induction. The rhLep protein, which has a molecular weight about 16kD, was purified by Ni2+ affinity chromatography column and identified by SDS-PAGE. The MTT Assay shows that rhLep promotes EC304 cells growth at the low concentration of 10ng/mL to 30 ng/mL, and rhLep appears cytotoxic to EC304 cells with the high dose of 50ng/mL to 225ng/mL. The viability of EC304 cells decreases to 1.2% with the concentration of 225ng/mL of rhLep. The massive apoptosis of rhLep on EC304 cells is observed by AO-staining under fluorescent microscope. All these results would lay the foundation for the further study of its biological functions in vitro and in vivo.
- Published
- 2006
34. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
- Author
-
Shi YK, Liu P, Yang S, Han XH, He XH, Ai B, Qin Y, Li B, Huang DZ, Zhang CG, and Sun Y
- Subjects
- Adult, Aged, Antigens, CD34 metabolism, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Antineoplastic Agents, Phytogenic adverse effects, Antineoplastic Agents, Phytogenic therapeutic use, Arthralgia chemically induced, Blood Cell Count, Carboplatin adverse effects, Carboplatin therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Fatigue chemically induced, Female, Granulocyte Colony-Stimulating Factor administration & dosage, Granulocyte Colony-Stimulating Factor adverse effects, Granulocyte Colony-Stimulating Factor chemistry, Humans, Injections, Subcutaneous, Male, Middle Aged, Neutropenia chemically induced, Neutropenia pathology, Neutrophils cytology, Paclitaxel adverse effects, Paclitaxel therapeutic use, Polyethylene Glycols chemistry, Recombinant Proteins, Breast Neoplasms drug therapy, Granulocyte Colony-Stimulating Factor therapeutic use, Lung Neoplasms drug therapy, Neutropenia drug therapy
- Abstract
Background & Objective: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is effective in the prophylaxis and management of chemotherapy-induced neutropenia, but requires daily administration because of its short half-life. Pegylated rhG-CSF (PEG-rhG-CSF) is a long-acting reagent that permits less frequent injection. This study was to evaluate the safety and tolerance of PEG-rhG-CSF in Chinese patients, and to explore its efficacy of enhancing absolute neutrophil count (ANC) and CD34+ cell count in peripheral blood., Methods: Naïve non-small lung cancer or breast cancer patients with normal bone marrow function were eligible for this open-labeled, dose-escalation trial. All patients received 2 cycles of chemotherapy of identical regimen. In cycle 1, rhG-CSF (150 microg/day) was administrated in case of febrile neutropenia or grade 4 neutropenia; in cycle 2, patients received a single injection of PEG-rhG-CSF (30 microg/kg, 60 microg/kg, 100 microg/kg, or 200 microg/kg) 48 h after administration of paclitaxel and carboplatin., Results: All the 16 patients enrolled (4 in each dose group) were evaluable for safety and efficacy of PEG-rhG-CSF. Main adverse events related to PEG-rhG-CSF were musculoskeletal pain or arthralgia (13/16), fatigue (10/16), dizziness (2/16), and injection-site pain (1/16). All adverse events were mild to moderate, and most of them were reversible without treatment. PEG-rhG-CSF enhanced ANC in a dose-dependent manner to some extent, and PEG-rhG-CSF at 60 microg/kg or higher doses prevented chemotherapy-induced neutropenia with sustained effect; CD34+ cells in peripheral blood were also increased., Conclusions: PEG-rhG-CSF is well tolerated, with no serious adverse event in this trial. The recommended dose of PEG-rhG-CSF for phase II trial is 100 microg/kg because of its adequate efficacy and less adverse events than those of 200 microg/kg.
- Published
- 2006
35. [Quality of life of malignant patients after autologous stem cell transplantation].
- Author
-
Ai B, Shi YK, He XH, Han XH, Zhao LY, Zhou SY, Liu P, Yang JL, Zhang CG, Huang DZ, Qin Y, and Yang S
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Male, Middle Aged, Postoperative Period, Surveys and Questionnaires, Transplantation, Autologous, Young Adult, Hematopoietic Stem Cell Transplantation, Quality of Life
- Abstract
Objective: To investigate the quality of life of Chinese malignant patients who treated with the high dose chemoradiotherapy combined with autologous stem cell transplantation (ASCT)., Methods: The data of 89 patients who answer the EORTC QLQ-C30 Chinese version 3.0 after finished ASCT and disease free were analyzed using SPSS 10.0., Results: The score of global health status and functional assessment were near or over 80, more than 80 percent of patient had good or very good global health status or function, the patients who were experiencing moderate or severe financial dysfunction, fatigue, dyspnea, sleeping disturbance and diarrhea were in 72.5% (65/89), 50.6% (45/89), 42.7% (38/89), 33.7% (30/89) and 32.5% (29/89) respectively. The score of dyspnea in female patients was significant higher than male patients (P = 0.024). The score of global health status (P = 0.000), physical function (P = 0.000), role function (P = 0.031) and social function (P = 0.029) became higher significantly with time from transplantation and the score of fatigue became lower (P = 0.020). The Hodgkin's lymphoma patients had higher score significantly in nausea & vomiting (P = 0.002) and dyspnea (P = 0.006) than NHL. The age at transplantation and evaluation took none effect on the score., Conclusion: Most patient have good global health status and function after autologous stem cell transplantation, they are more suffered from financial dysfunction, fatigue, dyspnea, sleeping disturbance and diarrhea. Females have more dyspnea symptoms, the quality of life of patient will improve gradually with the time from transplantation, the Hodgkin's lymphoma patients have more symptoms than non-Hodgkin's lymphoma patients, we do not find any effect of age at transplantation and assessment on the quality of life.
- Published
- 2005
36. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
- Author
-
Zhou SY, Shi YK, He XH, Zhang P, Dong M, Huang DZ, Yang JL, Zhang CG, Liu P, Yang S, and Feng FY
- Subjects
- Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Child, Cisplatin administration & dosage, Cisplatin adverse effects, Dexamethasone administration & dosage, Dexamethasone adverse effects, Drug Administration Schedule, Etoposide administration & dosage, Etoposide adverse effects, Female, Follow-Up Studies, Humans, Ifosfamide administration & dosage, Ifosfamide adverse effects, L-Lactate Dehydrogenase blood, Lymphoma, Non-Hodgkin blood, Lymphoma, Non-Hodgkin therapy, Male, Middle Aged, Neoplasm Recurrence, Local, Neutropenia chemically induced, Remission Induction, Survival Rate, Thrombocytopenia chemically induced, Transplantation, Autologous, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Non-Hodgkin drug therapy, Salvage Therapy, Stem Cell Transplantation
- Abstract
Background & Objective: So far, there is still no standard salvage regimen for relapsed or refractory non-Hodgkin's lymphoma (NHL). The response rates (RR) of NHL patients received common salvage regimens, such as DICE, ESHAP, MINE, and EPOCH, are only 30%-70%. This study was to evaluate the efficacy and safety of DICE regimen, as a salvage regimen, in treating patients with relapsed or refractory intermediate and high grade NHL., Methods: Thirty-five patients with relapsed or refractory intermediate and high grade NHL, who had been pretreated with chemotherapy dominated by CHOP or CHOP-like regimen with a median of 6 cycles (ranged 2-12 cycles), were salvaged by DICE regimen from Jun. 1999 to Jan. 2004. Of the 35 patients, 14 were T-cell original, and 21 were B-cell original., Results: The 35 patients received DICE regimen with a median of 4 cycles (ranged 2-7 cycles). All patients were assessable in the efficacy and adverse events. The total RR was 74.3% with complete response (CR) rate of 31.4%, median response time (MST) of 4 months (ranged 1-30 months), median time to failure (TTF) of 7 months (ranged 2-34 months),median survival time (MST) of 14 months (ranged 3-51 months), and 2-year survival rate of 33.3%. The RRs of T-cell and B-cell NHL were 85.7% and 66.7%. The CR rate was higher in T-cells NHL than in B-cell NHL (50.0% vs. 19.0%, P=0.073). Elevated serum lactate dehydrogenase (LDH) and bulky disease were high risk factors of the efficacy of DICE regimen (P < 0.05). The response to DICE reginmen was an independent prognostic factor of patients with relapsed or refractory NHL (P = 0.001). The major toxicity was myelosuppression. Incidences of neutropenia and thrombocytopenia of grade III-IV were 71.4% and 8.6%., Conclusions: DICE regimen is a safe and effective salvage regimen for the patients with relapsed or refractory intermediate and high grade advanced NHL. Elevated serum LDH and bulky disease are the adverse prognostic factors. The response to DICE regimen may directly influence survival time of patients with relapsed or refractory NHL.
- Published
- 2005
37. [Mobilization of autologous peripheral blood stem cells with etoposide and recombinant human granulocyte colony stimulating factor in malignant tumor patients].
- Author
-
Shi YK, He XH, Han XH, Yang JL, Liu P, Zhang CG, and Ai B
- Subjects
- Adolescent, Adult, Antineoplastic Agents, Phytogenic administration & dosage, Child, Dose-Response Relationship, Drug, Etoposide administration & dosage, Female, Granulocyte Colony-Stimulating Factor administration & dosage, Hematopoietic Stem Cell Transplantation, Hematopoietic Stem Cells physiology, Hodgkin Disease therapy, Humans, Male, Middle Aged, Recombinant Proteins, Antineoplastic Agents, Phytogenic pharmacology, Etoposide pharmacology, Granulocyte Colony-Stimulating Factor pharmacology, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cells drug effects, Lymphoma, Non-Hodgkin therapy
- Abstract
Objective: To observe the combined effect of etoposide (Vp-16) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) on mobilization of autologous peripheral blood stem cells (APBSC) in malignant tumor patients and find out the suitable dose of Vp-16., Methods: Thirty patients were randomly divided into two groups, 15 in each group. In group A, Vp-16 1000 mg/m(2) was injected intravenously in six divided doses, for 2 hours every 12 hours on day 1, 2 and 3. In group B, Vp-16 1500 mg/m(2) was injected intravenously in six divided doses for 3 hours every 12 hours on day 1, 2 and 3. rhG-CSF was given as a single daily injection subcutaneously at the dose of 300 microg.body(-1).day(-1) from the day of the nadir of white blood cell (WBC) to the day before the end of APBCS harvest. APBSC harvest started when WBC > or = 5.0 x 10(9)/L and finished when accumulated mononuclear cells (MNC) > or = 5 x 10(8)/kg or CD34+ cells > or = 2 x 10(6)/kg., Results: There was no significant difference between the time of nadir, nadir of WBC, absolute neutrophil count (ANC), the beginning time and continuous time of rhG-CSF given, the beginning time and continuous time of APBSC harvest. When the blood volume, flow rate and continuous time of apheresis were similar in each apheresis in the two groups, the number of APBSC in each harvest and total number of APBSC were also not significantly different between the two groups. The side effects induced by Vp-16 were also not significant different between the two groups., Conclusion: Vp-16 combined with rhG-CSF is a safe and highly effective method for APBSC mobilization, 1000 mg/m(2) and 1500 mg/m(2) of Vp-16 possess similar efficiency and side effects for APBSC mobilization.
- Published
- 2004
38. [Tropisetron in attenuation of nausea and vomiting in patients undergoing high-dose chemo-radiotherapy supported by autologous peripheral blood stem cell transplantation].
- Author
-
He XH, Shi YK, Yang JL, Zhang CG, Liu P, Zhou AP, Zhou SY, and Ai B
- Subjects
- Adolescent, Adult, Child, Combined Modality Therapy, Female, Humans, Indoles adverse effects, Male, Radiotherapy adverse effects, Transplantation, Autologous, Tropisetron, Antineoplastic Combined Chemotherapy Protocols adverse effects, Indoles therapeutic use, Nausea prevention & control, Neoplasms therapy, Peripheral Blood Stem Cell Transplantation, Vomiting prevention & control
- Abstract
Background & Objective: High-dose conditioning regimens of chemo-radiotherapy with or without total body irradiation (TBI) frequently induces nausea and vomiting in patients who are supported with stem cell transplantation. 5-Hydroxytrypamine(3) (5-HT(3)) receptor antagonists, when used alone, are unsatisfactory in the attenuation of emesis; Furthermore, consensus about their optimal dose, optimal dosing frequency and the combined use with other anti-emetic drugs are still controversial. The main objective of this trial was to observe the anti-emetic effectiveness and side effects of tropisetron plus dexamethasone and diphenhydramine (Group A) and tropisetron alone (Group B) on the patients undergoing high-dose treatment for peripheral blood stem cell (PBSC) mobilization and transplantation., Methods: From December 1998 to September 2002, 68 patients undergoing autologous peripheral blood stem cell transplantation were allotted into this study. All the eligible patients were divided into group A or B non-randomly to compare the efficacy of the two regimens in the prevention of nausea and vomiting induced by high-dose treatment. Regimens:40 patients in group A were given tropisetron 5 mg,iv,every 12 h plus dexamethasone 5-10 mg, iv, daily, and diphenhydramine, 20 mg, im, daily. Twenty-eight patients in group B were received tropisetron alone,5 mg,iv,every 12h., Results: For nausea during the acute phase, complete response rates of group A and B were 55% and 46.4%, with an overall response rates of 97.5% and 85.7%,of which the difference was insignificant (P >0.05). For vomiting during the acute phase, complete response rates of group A and B were 77.5% and 78.6%, with an overall response rates of 90% and 92.9%, of which the difference was insignificant (P >0.05). For delayed phase, both the complete response and overall response rates were higher in group A, with the difference significant (P< 0.05). The side effects of both regimens were mild. Common side effects including abdomen discomfort,headache,heavy head and constipation did not necessitate the discontinuity of high-dose treatment., Conclusion: The combination of tropisetron with dexamethasone and diphenhydramine is more effective than tropisetron alone in the control of nausea and vomiting induced by high-dose chemotherapy with or without TBI, which is especially more effective in the delayed phase of nausea and vomiting. The side effects of the combination regimen were mild. Based on these findings, we stress the importance of large randomized trials in the future.
- Published
- 2004
39. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
- Author
-
Shi YK, He XH, Han XH, Liu P, Yang JL, Zhou SY, Zhou AP, Zhang CG, and Ai B
- Subjects
- Adolescent, Adult, Antineoplastic Agents, Alkylating adverse effects, Antineoplastic Agents, Alkylating pharmacology, Antineoplastic Agents, Phytogenic adverse effects, Antineoplastic Agents, Phytogenic pharmacology, Child, Cyclophosphamide adverse effects, Etoposide adverse effects, Female, Hematopoietic Stem Cell Transplantation, Hematopoietic Stem Cells physiology, Humans, Male, Middle Aged, Cyclophosphamide pharmacology, Etoposide pharmacology, Granulocyte Colony-Stimulating Factor pharmacology, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cells drug effects, Peripheral Blood Stem Cell Transplantation
- Abstract
Background & Objective: It is important to get high quality autologous peripheral blood stem cell (APBSC) for successful peripheral blood stem cell transplantation. Cyclophosphamide (CTX) plus recombined human granulocyte colony-stimulating factor (rhG-CSF) is standard regimen for APBSC mobilization. Etoposide plus rhG-CSF is another regimen for mobilization in recent years. The purpose of this study was to observe and compare the effects of these two regimens in APBSC mobilization for the patients with malignant lymphoma and germ cell tumors., Methods: Fifty-two patients were divided into two groups according to the regimen of mobilization. In CTX group, 26 patients were injected CTX 3.5 g/m(2) intravenously. The other 26 patients in VP-16 group, VP-16 1000 mg/m(2) or 1500 mg/m(2) were given intravenously at random. All patients received rhG-CSF once daily as subcutaneous injection at the dose of 5 microg x kg(-1) x day(-1) from the day of the nadir of white blood cell (WBC) till the day before the last APBSC harvest in both groups. APBSC harvest was performed daily when WBC recovered more than 2.5x10(9)/L in CTX group and 5.0x10(9)/L in VP-16 group. APBSC harvest finished when accumulated mononuclear cells (MNCs) were more than 5x10(8)/kg or CD34(+) cells were more than 2x10(6)/kg. Collected APBSC was infused following condition regimen. Blood parameters, account of harvested cells, the time of hematopoietic reconstitute, and adverse effects were compared between two groups., Results: Following administration of CTX or VP-16, the nadirs of WBC and PLT in CTX group appeared significantly earlier than that in VP-16 group. The doses and times of rhG-CSF administration were not significantly different between the two groups. The start was later and the times of APBSC apheresis were less significantly in VP-16 group. The processed blood volume in single apheresis was more in VP-16 group. Speed and duration of single apheresis were similar in the two groups. Total MNCs were similar in the two groups, but the numbers of MNCs and CD34(+) cells collected in the first harvest and total number of CD34(+) cells collected were significantly more in VP-16 group. With equal quantity infusion of MNCs and CD34(+) cells infusion, hematopoietic reconstitution was achieved in both groups and the time of reconstitution was similar. Nausea and vomiting were more frequent in CTX group. Obvious PLT decrease was observed in VP-16 group. Other adverse effects were similar., Conclusion: CTX or VP-16 plus rhG-CSF both were safe and effective regimens for APBSC mobilization. More CD34(+) cells can be harvested by mobilization with VP-16 plus rhG-CSF than mobilization with CTX plus rhG-CSF. And the APBSC mobilized with VP-16 plus rhG-CSF can assure successful hematopoietic reconstitution.
- Published
- 2003
40. [Clinical and pathological features of 23 patients with primary lymphoma of the testis].
- Author
-
Yang JL, Shi YK, He XH, Zhou AP, Liu P, Ai B, and Zhang CG
- Subjects
- Adult, Aged, Humans, Lymphoma mortality, Lymphoma surgery, Male, Middle Aged, Retrospective Studies, Survival Rate, Testicular Neoplasms mortality, Testicular Neoplasms surgery, Lymphoma pathology, Testicular Neoplasms pathology
- Abstract
Objective: To study the clinical and pathological features of primary lymphoma of the testis and try to find out the rational treatment modality., Methods: Retrospective and follow-up analysis was conducted in 23 patients with primary lymphoma of the testis. Survival analysis was performed by Kaplan-Meier process., Results: The primary clinical symptom was painless tumefaction. 78.3% lesions were Stage I(E) on diagnosis. Most of them were intermediate grade B cell lymphoma. All patients received orchiectomy followed by chemotherapy and some followed by radiotherapy. The median survival time was 42 months. The overall survival rates at 1, 3 and 5 years were 100.0%, 59.8% and 36.5%, respectively. The disease-free survival rates at 1, 3 and 5 years were 66.7%, 42.3% and 36.3%, respectively., Conclusion: Primary lymphoma of the testis is preferably treated by multi-modality treatment. More than 6 cycles of chemotherapy is rational after orchiectomy. Regional radiotherapy tends to reduce the local relapse.
- Published
- 2003
41. [A clinical study of rhG-CSF in accelerating hematological recovery following autologous hematopoietic stem cells transplantation].
- Author
-
Yang JL, Shi YK, He XH, Zhou SY, Zhou AP, Han XH, Liu P, Zhang CG, and Ai B
- Subjects
- Adolescent, Adult, Child, Female, Follow-Up Studies, Humans, Male, Middle Aged, Recombinant Proteins, Transplantation Conditioning, Transplantation, Autologous, Granulocyte Colony-Stimulating Factor pharmacology, Hematopoietic Stem Cell Transplantation adverse effects, Peripheral Blood Stem Cell Transplantation adverse effects
- Abstract
Background & Objective: High dose chemotherapy and radiotherapy supported by autologous hematopoietic stem cells transplantation(AHSCT) can improve the efficacy of some malignant solid tumors. Successful AHSCT should owe to rational usage of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in some extent. The purpose of this study was to observe the role of rhG-CSF in hematological recovery after AHSCT for patients with solid tumors., Methods: A total of 130 patients with solid tumors were divided into two groups. The rhG-CSF group received rhG-CSF at the dose of 250-300 microg daily from day 6 until WBC recovering to 5.0 x 10(9)/L. The control group did not receive rhG-CSF after AHSCT., Results: A total of 132 person-times AHSCT were finished and 2 patients of them experienced twice transplantation. Twenty-four patients received autologous bone marrow transplantation (ABMT), 12 of them received rhG-CSF following AHSCT and the others did not. One hundred and six persons underwent autologous peripheral blood stem cells transplantation (APBSCT), 47 patients received rhG-CSF and 61 did not. (1)In rhG-CSF group and control group of ABMT,the median days of WBC up to 5.0 x 10(9)/L were 14 days and 24 days (P< 0.001),respectively. The median time of hospitalization was 33 days and 41 days (P< 0.05),respectively. There was no statistical difference in median time of PLT recovering to 20 x 10(9)/L and 50 x 10(9)/L in the two groups.(2)In rhG-CSF group and control group of APBSCT,the median time of WBC recovering to 5.0 x 10(9)/L were 10 days and 13 days (P< 0.01), respectively. The median time of hospitalization was 17 days and 20 days(P< 0.01),respectively. There was no significantly statistical difference in median time of PLT recovering to 50 x 10(9)/L in the two groups. (3)The frequency of infectious complication was no statistical difference between two groups (P=0.45)., Conclusion: rhG-CSF administration after AHSCT can obviously accelerate the recovery of WBC and shorten the time of hospitalization, but there is no significant effect on the recovery of PLT. Further study is needed to investigate whether rhG-CSF can reduce the infectious complication.
- Published
- 2003
42. Sequencing of p53 mutation in established human hepatocellular carcinoma cell line of HHC4 and HHC15 in nude mice.
- Author
-
Yang SM, Zhou H, Chen RC, Wang YF, Chen F, Zhang CG, Zhen Y, Yan JH, and Su JH
- Abstract
AIM:To set up cell lines of human hepatocellular carcinoma in nude mice for the research of cell biology and gene therapy.METHODS:Xenotransplantation of human hepatoma into nude mice was carried out and the growth rate, histopathology and immunology of the nude mice were studied. The DNA from xenografts were analyzed by HBV gen and PCR amplification of a fragment of p53 gene exon 7, which were identified by dot blot hybridization, restriction fragments length polymorphism and DNA sequencing.RESULTS:HHC4 and HHC15 cell lines could be successively transplanted in nude mice and the population doubling time was 7 and 5 days respectively. These strains retained the original characteristics of histopathology, secreting AFP and heteroploid karyotypes in human hepatocellular carcinoma. The fragment of HBV gene was detected in the genomic DNA of both hHCC4 and hHCC15, however only HHC4 secreted HBsAg.The mutation at 250 code (C A) and 249 code (G T) were detected respectively in the genomic DNA of HHC4 and HHC15.CONCLUSION:The two cell lines are useful material for the studying of cell biology and gene therapy in human hepatocellular carcinoma and provide molecular biological trace of relationship between high mortality of hepatoma and AFB1 severe pollution of the daily common foods in this district.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.